Advances in Renal Denervation in the Treatment of Hypertension
暂无分享,去创建一个
Shaojie Chen | Weijie Chen | Bin Xiong | Zhiyu Ling | Y. Yin | Y. Yin
[1] G. Mancia,et al. Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range. , 2022, Journal of the American College of Cardiology.
[2] Hang Liu,et al. The intrarenal blood pressure modulation system is differentially altered after renal denervation guided by different intensities of blood pressure responses , 2022, Hypertension Research.
[3] G. Mancia,et al. Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry , 2022, European heart journal. Quality of care & clinical outcomes.
[4] Manesh R. Patel,et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial , 2022, The Lancet.
[5] J. Ge,et al. Rationale and Design of Sympathetic Mapping/Ablation of Renal Nerves Trial (SMART) for the Treatment of Hypertension: a Prospective, Multicenter, Single-Blind, Randomized and Sham Procedure-Controlled Study , 2022, Journal of Cardiovascular Translational Research.
[6] Hang Liu,et al. Present Evidence of Determinants to Predict the Efficacy of Renal Denervation , 2022, International journal of hypertension.
[7] Namrata Krishnan,et al. Update on Renal Sympathetic Denervation for the Treatment of Hypertension , 2022, Current Cardiology Reports.
[8] K. Kario,et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial , 2022, The Lancet.
[9] S. Hiremath,et al. Rethinking Resistant Hypertension , 2022, Journal of clinical medicine.
[10] Yulong Xiong,et al. Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases , 2021, Frontiers in Cardiovascular Medicine.
[11] C. Kim,et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial , 2021, Hypertension Research.
[12] J. Qian,et al. Optimal Strategy for HIFU-Based Renal Sympathetic Denervation in Canines , 2021, Frontiers in Cardiovascular Medicine.
[13] Hang Liu,et al. Mapping Renal Innervations by Renal Nerve Stimulation and Characterizations of Blood Pressure Response Patterns , 2021, Journal of Cardiovascular Translational Research.
[14] G. Mancia,et al. Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPLICITY Registry with follow-up data of 3 years. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] M. Uder,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial , 2021, The Lancet.
[16] F. Mahfoud,et al. Device Therapy of Hypertension , 2021, Circulation research.
[17] M. Böhm,et al. The current status of renal denervation for the treatment of arterial hypertension. , 2021, Progress in cardiovascular diseases.
[18] P. Gosse,et al. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. , 2020, JACC. Cardiovascular interventions.
[19] Lawrence A Leiter,et al. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. , 2020, The Canadian journal of cardiology.
[20] A. Kirtane,et al. Device-based therapies for arterial hypertension , 2020, Nature Reviews Cardiology.
[21] Manesh R. Patel,et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial , 2020, The Lancet.
[22] A. Cremer,et al. Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study. , 2019, Hypertension.
[23] Hang Liu,et al. Selective renal denervation guided by renal nerve stimulation: mapping renal nerves for unmet clinical needs , 2019, Journal of Human Hypertension.
[24] Bo Zhang,et al. Selective Renal Denervation Guided by Renal Nerve Stimulation in Canine. , 2019, Hypertension.
[25] K. Kario,et al. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. , 2019, JACC. Cardiovascular interventions.
[26] T. Lohmeier,et al. Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[27] A. Kirtane,et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. , 2019, Circulation.
[28] G. Mancia,et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry , 2019, European heart journal.
[29] H. Thiele,et al. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN) , 2019, Circulation.
[30] M. Voskuil,et al. Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[31] P. Xiao,et al. Blood pressure elevation response to radiofrequency energy delivery: one novel predictive marker to long-term success of renal denervation , 2018, Journal of hypertension.
[32] G. Lip,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[33] Jackson T. Wright,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.
[34] S. Pocock,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial , 2018, The Lancet.
[35] Neil Chapman,et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial , 2018, The Lancet.
[36] M. Esler,et al. Selective vs. Global Renal Denervation: a Case for Less Is More , 2018, Current Hypertension Reports.
[37] R. Schmieder,et al. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV , 2017, Journal of hypertension.
[38] Neil Chapman,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.
[39] E. Kholmovski,et al. Effect of applied energy in renal sympathetic denervation with magnetic resonance guided focused ultrasound in a porcine model , 2017, Journal of therapeutic ultrasound.
[40] Bing Huang,et al. Impacts of Renal Sympathetic Activation on Atrial Fibrillation: The Potential Role of the Autonomic Cross Talk Between Kidney and Heart , 2017, Journal of the American Heart Association.
[41] B. Zrenner,et al. Renal Artery Vasodilation May Be An Indicator of Successful Sympathetic Nerve Damage During Renal Denervation Procedure , 2016, Scientific Reports.
[42] P. Gosse,et al. Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial , 2016, Circulation.
[43] J. Staessen,et al. Renal Nerve Stimulation–Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation , 2016, Hypertension.
[44] P. Neužil,et al. Externally Delivered Focused Ultrasound for Renal Denervation. , 2016, JACC. Cardiovascular interventions.
[45] J. Staessen,et al. Persistent Increase in Blood Pressure After Renal Nerve Stimulation in Accessory Renal Arteries After Sympathetic Renal Denervation , 2016, Hypertension.
[46] P. Xiao,et al. The effect of two different renal denervation strategies on blood pressure in resistant hypertension: Comparison of full‐length versus proximal renal artery ablation , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[47] R. Schmieder,et al. Non-invasive Renal Denervation: Update on External Ultrasound Approaches , 2016, Current Hypertension Reports.
[48] P. Blankestijn,et al. The morphological substrate for Renal Denervation: Nerve distribution patterns and parasympathetic nerves. A post-mortem histological study. , 2016, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.
[49] E. Kholmovski,et al. Renal sympathetic denervation using MR-guided high-intensity focused ultrasound in a porcine model , 2016, Journal of therapeutic ultrasound.
[50] S. Pocock,et al. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. , 2016, American heart journal.
[51] Que Zhu,et al. Noninvasive Renal Denervation for Resistant Hypertension Using High-Intensity Focused Ultrasound , 2015, Hypertension.
[52] B. Zrenner,et al. Selective Proximal Renal Denervation Guided by Autonomic Responses Evoked via High-Frequency Stimulation in a Preclinical Canine Model , 2015, Circulation. Cardiovascular interventions.
[53] P. Gosse,et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.
[54] Deepak L. Bhatt,et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.
[55] J. Staessen,et al. Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study , 2014, Journal of Human Hypertension.
[56] R. Virmani,et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. , 2014, Journal of the American College of Cardiology.
[57] Deepak L. Bhatt,et al. Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.
[58] S. Inci,et al. Assessment of effect of irbesartan and nebivolol on the left atrium volume and deformation in the patients with mild-moderate hypertension. , 2014, European review for medical and pharmacological sciences.
[59] Que Zhu,et al. Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. , 2013, Journal of the American College of Cardiology.
[60] K. Iijima,et al. Blood Pressure and Autonomic Responses to Electrical Stimulation of the Renal Arterial Nerves Before and After Ablation of the Renal Artery , 2013, Hypertension.
[61] H. Krum,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.
[62] Krzysztof Bartus,et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.